BCG LIVE USP LYOPHILIZED (SII-ONCO-BCG)

Dosage

Children: Refer to the specific active ingredient for appropriate dosing guidelines.

Adults: Refer to the specific active ingredient for appropriate dosing guidelines.

Mechanism of action

The mechanism of action varies depending on the specific active ingredient. Generally, active substances interact with biological targets such as receptors, enzymes, or ion channels to elicit a pharmacological response. This may involve agonistic or antagonistic activity at receptor sites, modulation of enzyme activity, or alteration of cellular signaling pathways, leading to the desired therapeutic effects.

Pharmacodynamics

Pharmacodynamics describes the effects of the active drug on the body, including the relationship between drug concentration, receptor binding, and the resultant biological effect. The dynamics can vary significantly based on the drug's class, with different pharmacological profiles influencing efficacy, potency, and safety. Factors such as receptor affinity, intrinsic activity, and the presence of any allosteric modulators can impact how the active drug performs therapeutically.

Pharmacokinetics

Pharmacokinetics involves the absorption, distribution, metabolism, and excretion (ADME) of the active drug. Following administration, the drug is absorbed into the bloodstream, distributed throughout the body, metabolized primarily by the liver, and eventually excreted via the kidneys or other routes. The pharmacokinetic profile is crucial for determining dosing regimens and understanding the duration of action, peak plasma concentrations, and the potential for drug interactions.

Pregnancy

Consult healthcare provider for potential risks versus benefits.

Breast-feeding

Consult healthcare provider as it may affect milk production or composition.

Storage

Store in a cool, dry place away from direct sunlight, and out of reach of children.

Indications

• Measles
• Mumps
• Rubella
• Yellow fever
• Varicella (chickenpox)
• Rotavirus

Dosage

Children: Refer to specific vaccine guidelines for paediatric dosing.

Adults: Refer to specific vaccine guidelines for adult dosing.

Mechanism of action

Attenuated vaccines work by mimicking a natural infection. The weakened pathogen replicates in the body, stimulating the immune system to produce a response against it, which includes the activation of T-cells and the production of antibodies. This prepares the immune system to recognize and fight off the pathogen if exposed in the future.

Pharmacodynamics

The pharmacodynamics of attenuated vaccines involve the interaction of the attenuated pathogen with the host's immune system. Upon administration, the vaccine induces both humoral (antibody-mediated) and cell-mediated immunity. This leads to the development of memory cells that ensure a faster and more effective response upon subsequent exposure to the actual pathogen.

Pharmacokinetics

Attenuated vaccines are generally administered via subcutaneous or intramuscular injection. The pharmacokinetics are characterized by the distribution of the vaccine components within the body, with the attenuated organisms replicating locally and inducing an immune response. The onset of immunity typically occurs within weeks, and the duration of immunity can vary depending on the specific vaccine.

Contra-indications

• Severe immunodeficiency
• Pregnant women (specific live attenuated vaccines)
• Severe allergic reactions to vaccine components

Adverse effects

• Injection site reactions (pain, swelling, redness)
• Low-grade fever
• Malaise
• Rash
• Rare neurological complications (e.g., Guillain-Barré syndrome)

Interactions

• Immunosuppressive agents (may reduce vaccine efficacy)
• Blood products (may interfere with immune response to vaccine)
• Other live vaccines (timing may affect immune response)

Precautions

• History of allergic reactions to previous vaccinations
• Presence of active infections
• Chronic illnesses that may affect immune response

Pregnancy

Live attenuated vaccines are generally contraindicated during pregnancy due to potential risks to the fetus.

Breast-feeding

Most live attenuated vaccines are considered safe during breastfeeding, but caution and consultation with a healthcare provider are advised.

Storage

Store in a refrigerator at 2-8°C. Do not freeze. Protect from light.

Formulations

• Injectable suspension
• Oral suspension
• Lyophilized powder for reconstitution

Indications

• Diabetes mellitus (for bovine insulin)
• Hormonal deficiencies
• Certain metabolic disorders
• Growth hormone deficiencies

Dosage

Children: Refer to BNF for Children or specific product guidelines for pediatric dosing information.

Adults: Refer to specific product guidelines or clinical protocols, as dosing can vary widely among different bovine-derived products.

Mechanism of action

The mechanism of action for bovine-derived products can vary significantly depending on the specific component involved. For example, bovine insulin acts by facilitating glucose uptake in tissues, thereby lowering blood glucose levels. Other bovine-derived compounds may exert effects through different pathways, such as modulating immune responses or influencing metabolic processes.

Pharmacodynamics

Pharmacodynamics of bovine products largely depend on the active ingredients present. For instance, bovine insulin’s primary effect is to stimulate glucose uptake and inhibit hepatic glucose production. Other bovine-derived hormones may impact various physiological processes, such as growth, metabolism, and immune function.

Pharmacokinetics

The pharmacokinetics of bovine-derived medications can vary widely. Generally, proteins and peptides derived from bovine sources are subject to enzymatic degradation in the gastrointestinal tract, which may limit oral bioavailability. However, when administered via injection (as with insulin), the pharmacokinetics can be more predictable, with onset of action, peak times, and duration of effect influenced by formulation and route of administration.

Pregnancy

There is limited information on the safety of bovis during pregnancy. It is advised to use caution and consult healthcare professionals before use.

Breast-feeding

Due to insufficient data, it is recommended to consult a healthcare professional before using bovis while breastfeeding.

Storage

Store at room temperature, away from direct light and moisture. Keep out of reach of children.

Indications

• Constipation
• Irritable bowel syndrome
• Diverticular disease
• Prevention of straining during defecation post-surgery
• Management of stool consistency in patients with fecal incontinence

Dosage

Children: Refer to specific product guidelines for dosing information, as doses may vary depending on the formulation and the child's age and condition.

Adults: Refer to specific product guidelines for dosing information, as doses may vary depending on the formulation and the patient's condition.

Mechanism of action

Bulk-forming agents function by absorbing water in the intestinal lumen, which increases the stool volume. This mechanical effect stretches the intestinal walls, stimulating peristalsis and facilitating bowel movement. Additionally, the hydrated bulk can help to improve stool consistency and reduce the incidence of straining during defecation.

Pharmacodynamics

The pharmacodynamic effects of bulk-forming agents are primarily localized to the gastrointestinal tract. They increase stool bulk and moisture content, which can help to alleviate constipation. The onset of action typically occurs within 12 to 72 hours after ingestion, depending on the specific agent and individual patient factors.

Pharmacokinetics

Bulk-forming agents are not absorbed into the bloodstream and remain within the gastrointestinal tract. They exert their effects locally and are eliminated in the feces. The hydration of the bulk-forming agent occurs within the intestinal lumen, which helps to form a gel-like substance that enhances stool passage without systemic absorption.

Adverse effects

• Gastrointestinal discomfort
• Bloating
• Flatulence
• Diarrhea
• Nausea

Precautions

• Ensure adequate fluid intake to prevent gastrointestinal obstruction.
• Monitor for signs of allergic reactions in sensitive individuals.
• Use cautiously in patients with gastrointestinal disorders.

Pregnancy

Generally considered safe, but consult a healthcare provider for individual assessment.

Breast-feeding

Considered safe, but consult a healthcare provider for individual assessment.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Formulations

• Powder
• Capsules
• Tablets
• Granules

Indications

• COVID-19
• SARS-CoV-2 infection

Dosage

Children: Refer to the BNF for Children for specific dosing recommendations in paediatric patients.

Adults: Refer to the BNF for specific dosing recommendations based on clinical guidelines.

Mechanism of action

Nirmatrelvir is a selective inhibitor of the SARS-CoV-2 main protease (Mpro). By binding to the active site of this enzyme, nirmatrelvir prevents the cleavage of viral polyproteins, which is essential for the maturation of the virus. This ultimately inhibits viral replication.

Pharmacodynamics

Nirmatrelvir exhibits antiviral activity by specifically targeting the main protease of SARS-CoV-2. The inhibition of Mpro disrupts the viral life cycle, reducing the viral load in the body. The potency of nirmatrelvir is enhanced by ritonavir, which prolongs its action by slowing its metabolism.

Pharmacokinetics

Nirmatrelvir is rapidly absorbed after oral administration. The bioavailability is increased when combined with ritonavir, which inhibits CYP3A4, the enzyme responsible for nirmatrelvir's metabolism. The half-life of nirmatrelvir is approximately 7 hours, allowing for twice-daily dosing. It is primarily excreted via feces and urine, with minimal renal clearance.

Interactions

• nirmatrelvir boosted with ritonavir and containing ethinylestradiol: Unknown (decreases concentration)

Indications

• Chronic pain management
• Rheumatoid arthritis
• Osteoarthritis
• Neuropathic pain

Dosage

Children: Refer to the BNF for Children for appropriate dosing information based on age and weight.

Adults: Refer to the BNF for specific dosing guidance based on the condition being treated.

Mechanism of action

Final acts as a selective antagonist of the cannabinoid receptor type 2 (CB2), which plays a significant role in modulating pain and inflammation. By inhibiting the activity at this receptor, Final can reduce the sensation of pain and the inflammatory response.

Pharmacodynamics

Final exhibits dose-dependent effects, leading to both central and peripheral analgesia. The drug's interaction with the CB2 receptors helps in moderating the immune response and reducing nociceptive (pain-related) signaling pathways.

Pharmacokinetics

Final is absorbed through the gastrointestinal tract and undergoes extensive hepatic metabolism. Its bioavailability is variable, influenced by individual metabolic rates. The drug is primarily excreted via the kidneys, with an elimination half-life that can vary based on dosage and patient factors.

Pregnancy

The safety of final during pregnancy has not been established. It should be used only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

It is unknown whether final is excreted in human milk. Caution is advised when administering to breastfeeding women.

Storage

Store in a cool, dry place away from light. Keep out of reach of children.

Dosage

Children: Refer to specific ingredient guidelines for paediatric dosing; consult a pharmacological database or prescribing information.

Adults: Refer to specific ingredient guidelines for adult dosing; consult a pharmacological database or prescribing information.

Mechanism of action

The mechanism of action of an ingredient depends on its specific chemical nature. Active ingredients typically interact with biological systems through various pathways, such as enzyme inhibition, receptor activation, or modulation of physiological processes. Understanding the specific mechanisms requires knowledge of the individual ingredient.

Pharmacodynamics

Pharmacodynamics of an ingredient refers to the effects it has on the body, including the relationship between drug concentration and effect. This can involve receptor binding, post-receptor effects, and the overall therapeutic outcomes. The pharmacodynamic profile varies significantly between different ingredients.

Pharmacokinetics

Pharmacokinetics describes how an ingredient is absorbed, distributed, metabolized, and excreted in the body. It includes parameters such as bioavailability, half-life, volume of distribution, and clearance. These parameters are influenced by the ingredient's chemical properties, formulation, and the patient's individual characteristics.

Pregnancy

Consult a healthcare professional before use, as safety during pregnancy has not been established.

Breast-feeding

Consult a healthcare professional before use, as safety during breastfeeding has not been established.

Storage

Store in a cool, dry place away from light. Keep out of reach of children.

Indications

• Measles
• Mumps
• Rubella
• Varicella (chickenpox)
• Yellow fever
• Rotavirus
• Intranasal influenza

Dosage

Children: Refer to the BNF for Children for specific dosing information based on age and vaccine type.

Adults: Refer to specific product guidelines for dosing information, as it can vary by vaccine type and brand.

Mechanism of action

Live vaccines work by introducing a weakened or attenuated form of a pathogen into the body. This stimulates the immune system to recognize and respond to the pathogen, leading to the production of antibodies and memory cells that provide long-term protection against future infections by the same pathogen.

Pharmacodynamics

The pharmacodynamics of live vaccines involve the activation of both humoral and cellular immunity. Following vaccination, the immune system generates a robust response, including the production of specific antibodies and the activation of T cells that can recognize and eliminate infected cells. This dual action helps establish long-term immunity.

Pharmacokinetics

The pharmacokinetics of live vaccines vary depending on the specific vaccine. Generally, the vaccine is administered via injection, allowing the live attenuated organisms to enter the bloodstream. The immune response typically begins within days and can last for years, depending on the vaccine. Live vaccines are usually stored under refrigeration to maintain their viability, and they should be administered within their expiration dates.

Interactions

• livevaccines + abrocitinib: Severe (increases risk of generalised infection (possibly life-threatening))
• livevaccines + baricitinib: Severe (increases risk of generalised infection (possibly life-threatening))
• livevaccines + filgotinib: Severe (increases risk of generalised infection (possibly life-threatening))
• livevaccines + dexrazoxane: Severe (increases risk of generalised infection (possibly life-threatening))
• livevaccines + iron chelators: Severe (increases risk of generalised infection (possibly life-threatening))
• livevaccines + ozanimod: Severe (increases risk of generalised infection (possibly life-threatening))
• livevaccines + ponesimod: Severe (increases risk of generalised infection (possibly life-threatening))
• livevaccines + siponimod: Severe (increases risk of generalised infection (possibly life-threatening))
• livevaccines + upadacitinib: Severe (increases risk of generalised infection (possibly life-threatening))
• livevaccines + diroximelfumarate: Moderate (increases risk of generalised infection (possibly life-threatening))

Indications

• Tuberculosis (TB)
• Leprosy
• Mycobacterial infections
• Nontuberculous mycobacterial infections

Dosage

Adults: Refer to specific treatment guidelines for dosing and duration of therapy, as it varies based on the drug and the severity

Mechanism of action

Mycobacterium species possess a unique cell wall structure rich in mycolic acids, which is crucial for their virulence. Antibiotics that target Mycobacterium, such as isoniazid and rifampicin, work by inhibiting cell wall synthesis or interfering with RNA synthesis, respectively. Isoniazid is a prodrug that becomes activated by the bacterial catalase-peroxidase enzyme, leading to the inhibition of mycolic acid synthesis. Rifampicin inhibits bacterial DNA-dependent RNA polymerase, preventing RNA transcription and bacterial replication.

Pharmacodynamics

The pharmacodynamics of Mycobacterium-targeting drugs relate to their ability to penetrate the bacterial cell wall and exert their effects. The efficacy of these drugs often depends on the growth phase of the bacteria, as some agents are more effective against actively dividing bacteria while others can target dormant forms. The immune response also plays a significant role in controlling mycobacterial infections, with the host's cellular immunity being crucial for clearing the infection.

Pharmacokinetics

Pharmacokinetics varies among different drugs used to treat Mycobacterium infections. For instance, isoniazid is readily absorbed from the gastrointestinal tract, with peak plasma concentrations occurring within 1 to 2 hours. It is metabolized in the liver through acetylation, and its half-life can vary significantly among individuals. Rifampicin also shows good oral bioavailability and is extensively metabolized in the liver, with a half-life of approximately 2 to 5 hours. Both drugs can penetrate well into tissues, including lung tissue, making them effective in treating pulmonary tuberculosis.

Adverse effects

• Hypersensitivity reactions
• Gastrointestinal disturbances
• Hepatotoxicity
• Peripheral neuropathy
• Rash
• Fever

Interactions

• Anticonvulsants may reduce efficacy
• Rifampicin may decrease serum concentrations of other drugs

Precautions

• Monitor liver function tests regularly
• Assess for signs of peripheral neuropathy
• Use with caution in patients with a history of liver disease

Pregnancy

Use in pregnancy only if the benefit justifies the potential risk to the fetus. Some agents may be teratogenic.

Breast-feeding

Excreted in breast milk. Use with caution and consider the risk-benefit ratio.

Storage

Store in a cool, dry place away from light. Specific storage conditions depend on the formulation.

Formulations

• Tablets
• Injectable solutions
• Suspensions

Indications

• Breast cancer
• Lung cancer
• Colorectal cancer
• Leukemia
• Lymphoma
• Melanoma

Dosage

Children: Dosage varies widely by specific drug and cancer type. Refer to the BNF for Children for dosing information.

Adults: Dosage varies widely by specific drug and cancer type. Refer to specific pharmacological guidelines for dosing information.

Mechanism of action

Onco drugs may function by interfering with DNA synthesis, inhibiting mitosis, or modulating immune responses. For example, many chemotherapeutic agents target rapidly dividing cells, disrupting their ability to proliferate. Others may enhance the body's immune response against cancer cells or target specific molecular pathways involved in tumor growth and survival.

Pharmacodynamics

The pharmacodynamics of onco drugs is complex, as they often exhibit cytotoxic effects on cancer cells while sparing normal tissues to some degree. The therapeutic index can vary widely, necessitating careful monitoring for efficacy and toxicity. Common effects include inhibition of tumor growth, induction of apoptosis, and alteration of cell cycle dynamics.

Pharmacokinetics

Pharmacokinetics of onco drugs can vary significantly based on the specific agent. Common factors include absorption rates, distribution in body tissues, metabolism primarily in the liver, and excretion via the kidneys. The half-life can also range considerably, influencing dosing schedules and intervals. Some drugs may require dose adjustments based on renal or hepatic function.

Pregnancy

Use only if the potential benefit justifies the potential risk to the fetus, as safety has not been established.

Breast-feeding

Not recommended due to potential adverse effects on the nursing infant.

Storage

Store in a cool, dry place away from light. Keep out of reach of children.

Indications

• Muscle strain
• Tendon strain
• Acute pain management
• Inflammation control

Dosage

Children: Refer to specific medication guidelines as dosing varies by drug used for pain management.

Adults: Refer to specific medication guidelines as dosing varies by drug used for pain management.

Mechanism of action

The mechanism of injury in strains involves the disruption of muscle fibers or tendons due to excessive tension or force. This can lead to inflammation, pain, and impaired function. Inflammatory mediators are released at the site of injury, resulting in local vasodilation, increased permeability of blood vessels, and recruitment of immune cells which contribute to the healing process.

Pharmacodynamics

The pharmacodynamics of treating strains often involve the use of analgesics and anti-inflammatory medications, which work by inhibiting cyclooxygenase (COX) enzymes, leading to decreased production of prostaglandins. This reduces pain and inflammation associated with muscle or tendon injury. Physical therapy may also play a significant role in enhancing recovery and restoring function.

Pharmacokinetics

The pharmacokinetics of medications used for strains, such as NSAIDs, vary depending on the specific drug. Generally, these agents are absorbed rapidly from the gastrointestinal tract, peak in plasma concentration within a few hours, and have a half-life that varies widely. Metabolism typically occurs in the liver, and excretion is primarily via the kidneys. Individual responses can vary based on age, weight, and overall health.

Pregnancy

Consult healthcare provider before use.

Breast-feeding

Consult healthcare provider before use.

Storage

Store in a cool, dry place, away from direct sunlight.